GERN Quote, Financials, Valuation and Earnings

Ultragenyx Pharmaceutical, Inc. has a net margin of -39.02% compared to Geron Corp.'s net margin of -112.81%. Geron Corp.'s return on equity of -29.65% beat Ultragenyx Pharmaceutical, Inc.'s return on equity of -307.83%.

Geron Corp. has a consensus price target of $3.60, signalling upside risk potential of 174.81%. On the other hand Ultragenyx Pharmaceutical, Inc. has an analysts' consensus of $64.95 which suggests that it could grow by 188.8%. Given that Ultragenyx Pharmaceutical, Inc. has higher upside potential than Geron Corp., analysts believe Ultragenyx Pharmaceutical, Inc. is more attractive than Geron Corp..

Geron Corp. has a beta of 0.594, which suggesting that the stock is 40.567% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical, Inc. has a beta of 0.155, suggesting its less volatile than the S&P 500 by 84.518%.

Geron Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron Corp. pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical, Inc. pays out -- of its earnings as a dividend.

Geron Corp. quarterly revenues are $47.2M, which are smaller than Ultragenyx Pharmaceutical, Inc. quarterly revenues of $159.9M. Geron Corp.'s net income of -$18.4M is higher than Ultragenyx Pharmaceutical, Inc.'s net income of -$180.4M. Notably, Geron Corp.'s price-to-earnings ratio is -- while Ultragenyx Pharmaceutical, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron Corp. is 4.76x versus 3.48x for Ultragenyx Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Rezolute, Inc. has a net margin of -39.02% compared to Geron Corp.'s net margin of --. Geron Corp.'s return on equity of -29.65% beat Rezolute, Inc.'s return on equity of -63.8%.

Geron Corp. has a consensus price target of $3.60, signalling upside risk potential of 174.81%. On the other hand Rezolute, Inc. has an analysts' consensus of $4.25 which suggests that it could grow by 55.68%. Given that Geron Corp. has higher upside potential than Rezolute, Inc., analysts believe Geron Corp. is more attractive than Rezolute, Inc..

Geron Corp. has a beta of 0.594, which suggesting that the stock is 40.567% less volatile than S&P 500. In comparison Rezolute, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 61.035%.

Geron Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Rezolute, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron Corp. pays -- of its earnings as a dividend. Rezolute, Inc. pays out -- of its earnings as a dividend.

Geron Corp. quarterly revenues are $47.2M, which are larger than Rezolute, Inc. quarterly revenues of --. Geron Corp.'s net income of -$18.4M is lower than Rezolute, Inc.'s net income of -$18.2M. Notably, Geron Corp.'s price-to-earnings ratio is -- while Rezolute, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron Corp. is 4.76x versus -- for Rezolute, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cassava Sciences, Inc. has a net margin of -39.02% compared to Geron Corp.'s net margin of --. Geron Corp.'s return on equity of -29.65% beat Cassava Sciences, Inc.'s return on equity of -86.98%.

Geron Corp. has a consensus price target of $3.60, signalling upside risk potential of 174.81%. On the other hand Cassava Sciences, Inc. has an analysts' consensus of $8.00 which suggests that it could grow by 292.16%. Given that Cassava Sciences, Inc. has higher upside potential than Geron Corp., analysts believe Cassava Sciences, Inc. is more attractive than Geron Corp..

Geron Corp. has a beta of 0.594, which suggesting that the stock is 40.567% less volatile than S&P 500. In comparison Cassava Sciences, Inc. has a beta of -1.000, suggesting its less volatile than the S&P 500 by 200.015%.

Geron Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cassava Sciences, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron Corp. pays -- of its earnings as a dividend. Cassava Sciences, Inc. pays out -- of its earnings as a dividend.

Geron Corp. quarterly revenues are $47.2M, which are larger than Cassava Sciences, Inc. quarterly revenues of --. Geron Corp.'s net income of -$18.4M is lower than Cassava Sciences, Inc.'s net income of -$10.8M. Notably, Geron Corp.'s price-to-earnings ratio is -- while Cassava Sciences, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron Corp. is 4.76x versus 2.69x for Cassava Sciences, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

SELLAS Life Sciences Group, Inc. has a net margin of -39.02% compared to Geron Corp.'s net margin of --. Geron Corp.'s return on equity of -29.65% beat SELLAS Life Sciences Group, Inc.'s return on equity of -103.86%.

Geron Corp. has a consensus price target of $3.60, signalling upside risk potential of 174.81%. On the other hand SELLAS Life Sciences Group, Inc. has an analysts' consensus of $6.83 which suggests that it could grow by 71.69%. Given that Geron Corp. has higher upside potential than SELLAS Life Sciences Group, Inc., analysts believe Geron Corp. is more attractive than SELLAS Life Sciences Group, Inc..

Geron Corp. has a beta of 0.594, which suggesting that the stock is 40.567% less volatile than S&P 500. In comparison SELLAS Life Sciences Group, Inc. has a beta of 2.262, suggesting its more volatile than the S&P 500 by 126.208%.

Geron Corp. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. SELLAS Life Sciences Group, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Geron Corp. pays -- of its earnings as a dividend. SELLAS Life Sciences Group, Inc. pays out -- of its earnings as a dividend.

Geron Corp. quarterly revenues are $47.2M, which are larger than SELLAS Life Sciences Group, Inc. quarterly revenues of --. Geron Corp.'s net income of -$18.4M is lower than SELLAS Life Sciences Group, Inc.'s net income of -$6.8M. Notably, Geron Corp.'s price-to-earnings ratio is -- while SELLAS Life Sciences Group, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Geron Corp. is 4.76x versus -- for SELLAS Life Sciences Group, Inc.. Usually stocks with elevated PS ratios are considered overvalued.